Biogazelle and Isis evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

October 15, 2015 Leave a comment 2,931 Views

GHENT, Belgium, October 15, 2015 – Biogazelle NV today announced a research-stage collaboration with Isis Pharmaceuticals in which they will identify and validate novel targets to treat colon, liver and lung cancer, diseases with clear unmet clinical needs. As part ...

RNA-Seq Blog Transcriptome Research & Industry News

Tag Archives: Isis Pharmaceuticals

Biogazelle and Isis evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

DeepVelo – single-cell transcriptomic deep velocity field learning with neural ordinary differential equations

$1.19 million grant will leverage single-cell sequencing technology

Improved bacterial single-cell RNA-seq

The mystery of the origins of introns solved

Envisagenics Announces Research Collaboration with Bristol Myers Squibb

Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer

Single-cell sequencing – promises and challenges for human genetics